Recombinant full-length Plasmodium falciparum circumsporozoite protein-based vaccine adjuvanted with GLA-LSQ: Results of Phase 1 testing with malaria challenge
2/2024
Journal Article
Authors:
Friedman-Klabanoff, D. J.;
Berry, A. A.;
Travassos, M. A.;
Shriver, M.;
Cox, C.;
Butts, J.;
Lundeen, J. S.;
Strauss, K. A.;
Joshi, S.;
Shrestha, B.;
Mo, A. X.;
Nomicos, E. Y. H.;
Deye, G. A.;
Regules, J. A.;
Bergmann-Leitner, E. S.;
Pasetti, M. F.;
Laurens, M. B.
Journal:
J Infect Dis
PMID:
38330357
URL:
https://www.ncbi.nlm.nih.gov/pubmed/38330357
Keywords:
Plasmodium falciparum
Gla-lsq
circumsporozoite protein
controlled human malaria infection
malaria
malaria vaccine
Abstract:
NTRODUCTION: Malaria is preventable yet causes >600,000 deaths annually. RTS, S, the first marketed malaria vaccine, has modest efficacy, but improvements are needed for eradication. METHODS: We conducted an open-label, dose escalation Phase 1 study of a recombinant, full-length circumsporozoite protein vaccine (rCSP) administered with adjuvant GLA-LSQ on days 1, 29, and 85 or 1 and 490 to healthy, malaria-naive adults. Primary endpoints were safety and reactogenicity. Secondary endpoints were antibody responses and Plasmodium falciparum parasitemia after homologous controlled human malaria infection (CHMI). RESULTS: Participants were enrolled into four groups receiving rCSP/GLA-LSQ: 10 microg x 3 (n = 20), 30 microg x 3 (n = 10), 60 microg x 3 (n = 10) or 60 microg x 2 (n = 9); ten participants received 30 microg rCSP alone x 3; and six infectivity controls. Participants experienced no serious adverse events. Rates of solicited and unsolicited adverse events were similar among groups. All 26 participants who underwent CHMI 28 days after final vaccinations developed malaria. Increasing vaccine doses induced higher IgG titers, but did not achieve previously established RTS, S benchmarks. CONCLUSIONS: rCSP/GLA-LSQ had favorable safety results. However, tested regimens did not induce protective immunity. Further investigation could assess if adjuvant or schedule adjustments improve efficacy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT03589794.
